Compare ACADIA Pharmaceuticals Inc. (ACAD) vs AXT Inc (AXTI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs AXT Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while AXT Inc trades at $60.07 (market cap $3.80B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, AXT Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | AXTI | |
|---|---|---|
Market Cap | $4.49B | $3.80B |
Sector | Health | Technology |
52-Week High | $28.06 | $140.83 |
52-Week Low | $20.06 | $1.92 |
Enterprise Value | $3.69B | $3.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AXTI trades at $63.52, up 12.19% today, but remains in a bearish technical trend with support at $60 and resistance at $64. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improving margins. Recent news highlights strong AI-driven demand for indium phosphide and a record $100M backlog, with earnings scheduled for July 30, 2026.
Outlook is mixed: analyst consensus is bullish (64% buy ratings) based on AI growth potential, but profitability challenges and geopolitical risks in China pose significant headwinds. The stock's high P/S ratio of 30.7 suggests premium valuation despite current losses, making execution critical for upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About AXT Inc
AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.
Read more on AXTI →
